Experimental Metabolic Therapy Successfully Starves Aggressive Pediatric Brain Cancer Cells in New Johns Hopkins Study

Johns Hopkins researchers find that stopping energy production in group 3 medulloblastoma tumors can slow growth and offer a new path for pediatric cancer therapy.

By: AXL Media

Published: May 1, 2026, 11:30 AM EDT

Source: Information for this report was sourced from EurekAlert!

New Hope for Combating Lethal Pediatric Neurological Tumors

Investigators at the Johns Hopkins Kimmel Cancer Center have uncovered a potential therapeutic breakthrough for treating group 3 medulloblastoma, one of the most aggressive forms of pediatric brain cancer. By focusing on the metabolic processes of cancer cells, the research team demonstrated that disrupting energy production can significantly inhibit tumor expansion. According to Ranjan Perera, the director of the Center for RNA Biology at Johns Hopkins All Children’s Hospital, there is an urgent and critical requirement for innovative treatments for this specific cancer, and the latest evidence suggests that tumor metabolism is a viable new target for medical intervention.

The Role of Non-Coding RNA in Fueling Cancer Growth

The research highlights a specific piece of non-coding RNA, known as lnc-HLX-2-7, which plays a pivotal role in the rapid development of medulloblastoma. This RNA molecule does not create proteins but instead interacts with DNA to increase the expression of the HLX gene, a known promoter of explosive tumor growth. The study found that this genetic interaction forces the cancer cells to consume more oxygen and produce higher levels of energy, essentially providing the fuel necessary for the disease to spread. By understanding this molecular mechanism, scientists are better positioned to design treatments that interfere with the metabolic reprogramming typical of aggressive pediatric tumors.

Nanoparticle Delivery Systems and Molecular Interference

Building on previous work from 2024, the team utilized serum oxide nanoparticles to deliver targeted therapies directly to the brain in laboratory models. This sophisticated delivery method allows for the blocking of lnc-HLX-2-7, preventing it from binding to DNA and subsequently reversing the surge in oxygen consumption within the tumor. When this binding process is interrupted, the tumor cells are effectively starved of the energy required to survive, leading to cellular death. This targeted approach offers a precision medicine alternative to traditional treatments, focusing specifically on the unique biological weaknesses of the cancer.